Prolonged treatment free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

Treatment-free remission (TFR) has become a new frontier in the treatment of patients with chronic myeloid leukemia (CML). Prospective clinical trials have shown that around 50% of patients in sustained deep molecular response can successfully discontinue their tyrosine kinase inhibitor (TKI)